MH PHARM | Venlafaxine

Core Profile and Mechanism Venlafaxine is an oral Serotonin Norepinephrine Reuptake Inhibitor (SNRI) indicated for adult major depressive disorder, generalized anxiety disorder, social anxiety, and panic disorder. It functions by inhibiting the central reuptake of serotonin and norepinephrine, possessing a 30-fold higher affinity for serotonin compared to norepinephrine. The drug is primarily metabolized in the liver via the CYP2D6 enzyme into its major active metabolite, O-desmethylvenlafaxine (ODV). Medications that inhibit CYP2D6 can dangerously elevate venlafaxine plasma concentrations, particularly in CYP2D6 poor metabolizers.Administration and Dosing Standard adult dosing typically begins at 37.5 mg or 75 mg daily. Maximum recommended dosages are generally 225 mg/day for outpatients, though severely depressed hospitalized inpatients may require and tolerate doses up to 375 mg/day. All doses must be taken with food to minimize gastrointestinal side effects. Extended-release capsules must be swallowed whole, or their contents can be sprinkled onto applesauce and swallowed immediately without chewing. Crucially, patients with mild-to-moderate hepatic or renal impairment require total daily dosage reductions ranging from 25% to 50%, while severe organ impairment necessitates reductions of 50% or more.Boxed Warnings and Pediatric Use A critical Black Box Warning highlights an increased risk of suicidal thoughts and behaviors in patients 24 years of age and younger. Venlafaxine's safety and efficacy are not established for children or adolescents under 18. Furthermore, pediatric trials have demonstrated dose-dependent weight loss and significant growth inhibition; therefore, any off-label pediatric use necessitates regular height and weight monitoring.Primary Adverse Reactions The most common mild side effects include nausea (21-58%), headache (25-38%), weight loss, insomnia, dry mouth, dizziness, and sweating. Moderate adverse effects frequently feature sexual dysfunction, such as ejaculation issues (8-19%), decreased libido, and constipation. Because it is an SNRI, venlafaxine can elevate blood pressure and heart rate, and is associated with increased bleeding events. Rare but severe clinical risks include serotonin syndrome, neuroleptic malignant syndrome, gastrointestinal bleeding, QTc prolongation, and Stevens-Johnson syndrome.Off-Label Uses Beyond its primary psychiatric approvals, venlafaxine serves as a first-line non-hormonal therapy for menopausal hot flashes and those associated with breast cancer treatments, effectively utilizing lower doses of 37.5 mg to 75 mg daily. It is also effective for premenstrual dysphoric disorder (PMDD) using continuous or luteal-phase dosing, painful diabetic neuropathy, fibromyalgia, and migraine prophylaxis. According to psychiatric guidelines, it acts as a second-line agent for obsessive-compulsive disorder (OCD) when patients fail initial SSRI therapies.Pharmacokinetics The absolute bioavailability of venlafaxine is approximately 45%. The elimination half-life is 5 hours for the parent drug and 11 hours for the ODV metabolite. Steady-state plasma concentrations are achieved within three days of multiple-dose therapy. Sudden discontinuation of the medication may precipitate early withdrawal symptoms.